fiercepharma
Today, there are clear signs that the biopharmaceutical industry is facing a quiet yet potentially damaging force: compressive disruption. However, future-focused biopharma companies have found a way to deliver exceptional growth amidst compressive disruption: by embracing New Science, an ever-evolving combination of the best in science and health technology that is filling unmet need and raising the standard of care. Accenture research finds that leaders in New Science are investing 6-7x more in digital, data and genomics compared to their peers.
Watch Now
Ambry Genetics
An introduction to study designs for investigating the role of genes in disease will be provided, followed by an overview of statistical methods used to test hypotheses for each design. Examples of several designs will be discussed, as well as accompanying methods. Publications assessing the role of genetic variation in disease will be examined, and a critical critique of methods and results for each publication will be reviewed.
Watch Now
questexweb
It was reported that over 79,000 people died of flu in the U.S. in the winter of 2017-2018, which was the highest death toll in four decades.1 It seems like the 2018-2019 flu season isn’t so bad. How are sales of OTC drugs impacted by the severity of flu seasons? Are there any opportunities for new products to capture market share? How can companies ensure reliable supply of OTC medications based upon expected spikes in demand?
Watch Now
Lorman
Many Health Information Management departments are still prepping charts that come from all departments of a hospital system. This means that there is a potential time lag in making this critical information available to providers. The first place to start is selecting a document imaging solution for any paper being produced outside of your EMR system. But let's take this a step further. What if we move document imaging out of the HIM department and into each clinical area of a hospital?
Watch Now